Rosai-Dorfman disease is a rare disorder in which certain immune cells called histiocytes accumulate abnormally, most often causing dramatically swollen lymph nodes in the neck. First described in 1969, it belongs to a family of conditions known as non-Langerhans cell histiocytoses and carries a hallmark cellular feature that pathologists look for under the microscope: large, pale histiocytes engulfing intact lymphocytes and other cells, a phenomenon called emperipolesis.1PubMed Central. Rosai-Dorfman disease. A legacy of Professor Rosai that is still not exploited completely Though the disease is often benign and self-limiting, it can behave unpredictably, and its tendency to mimic lymphoma and other serious conditions makes it a diagnosis that catches both patients and clinicians off guard.
What Happens in the Body
In healthy tissue, histiocytes are part of the immune system’s cleanup crew. In Rosai-Dorfman disease (often shortened to RDD), a subset of these cells proliferates excessively and accumulates in lymph nodes or other tissues. The defining oddity is emperipolesis, where a histiocyte actively engulfs another living cell, usually a lymphocyte, and holds it inside its own cytoplasm without destroying it. This is not ordinary phagocytosis, where a cell swallows and digests debris. The engulfed cell remains intact, sitting inside the histiocyte as though it were a passenger.2PubMed Central. Cytological Diagnosis of Rosai–Dorfman Disease: A Study of Twelve Cases with Emphasis on Diagnostic Challenges It is this feature, visible on biopsy slides, that separates RDD from other histiocytic disorders and drives the diagnostic workup.
Why these histiocytes behave this way is still not fully understood. For decades, RDD was considered a purely reactive or inflammatory process, possibly triggered by viral infections or immune dysregulation. That picture has shifted. Genetic studies have found that roughly a third of RDD cases carry mutations in either the KRAS or MAP2K1 genes, both of which activate a well-known cellular signaling cascade called the MAPK/ERK pathway.3PubMed Central. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease These mutations are the same kind that drive certain cancers, and their presence in RDD suggests that at least some cases are clonal, meaning the abnormal histiocytes descend from a single rogue cell rather than arising as a generalized inflammatory response. The remaining two-thirds of cases without detectable mutations may still be reactive, or they may carry genetic changes researchers have not yet identified.
How It Typically Shows Up
The classic presentation is painless, impressively enlarged lymph nodes on both sides of the neck in a young person who otherwise feels fine. Fever often accompanies the swelling. Blood work tends to show a constellation of nonspecific abnormalities: a high sedimentation rate, elevated white cell counts, mild anemia, and raised immunoglobulin levels.4PubMed Central. Rosai-Dorfman disease as a rare cause of cervical lymphadenopathy – case report and literature review None of these findings point specifically to RDD. They look like what you might see with an infection or a lymphoma, which is precisely why the disease is so often misdiagnosed at first.
Although neck lymph nodes are the most common location, RDD is not exclusively a nodal disease. Roughly 40 to 43 percent of patients have extranodal involvement, meaning the disease shows up in tissues other than lymph nodes.5PubMed. Rosai-Dorfman Disease: Manifestations Outside of the Head and Neck In about a quarter of cases, the disease appears at extranodal sites without any lymph node enlargement at all.6Oxford Medical Case Reports. Rosai-Dorfman disease presenting as autoimmune hemolytic anemia in a male child in Palestine: a case report
Where Else It Can Appear
The list of tissues that can harbor RDD is surprisingly long. Skin, soft tissue, the central nervous system, the gastrointestinal tract, and breast tissue have all been documented.7PubMed Central. Extranodal Rosai-Dorfman Disease- a Review of Diagnostic Testing and Management In the head and neck region, the nasal cavity is involved most frequently, followed by the throat, paranasal sinuses, and trachea.8Hematology/Oncology and Stem Cell Therapy. Rosai-Dorfman disease of the paranasal sinuses and orbit Orbital involvement can produce bulging eyes, blurred vision, and double vision.
Central nervous system RDD deserves special mention because it can create real diagnostic confusion. When the disease attaches to the membranes surrounding the brain, it forms masses on imaging that look almost identical to meningiomas, the most common benign brain tumor. One reported case involved a 28-year-old man who presented with a seizure and a mass along the brain’s lining that was presumed to be a meningioma until tissue was examined after surgery.9PubMed. Dural-based Rosai-Dorfman disease: differential diagnostic considerations A neuroradiology case series found involvement in sites including the meninges, the pituitary gland, spinal membranes, and paranasal sinuses.10PubMed. Rosai-Dorfman disease in neuroradiology: imaging findings in a series of 10 patients
Purely cutaneous RDD, where the disease is confined to the skin without lymph node involvement, is rarer but increasingly recognized in the literature.11PubMed. Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case These patients develop reddish-brown or yellowish nodules or plaques, sometimes on the face, that can be mistaken for other skin conditions. The cutaneous form tends to follow a more indolent course than disease involving internal organs.
Getting the Diagnosis Right
There is no simple blood test for RDD. The diagnosis rests on tissue biopsy and what the pathologist sees under the microscope. The key features are large histiocytes demonstrating emperipolesis, which stain positive for the markers S100 and CD68 but negative for CD1a.12PubMed Central. Clinicopathological Features, Treatment Response, and Outcome of Rosai-Dorfman Disease in Two Children That CD1a negativity is what distinguishes RDD from Langerhans cell histiocytosis (LCH), a different histiocytic disorder whose cells are CD1a-positive and have a different nuclear shape.13American Journal of Clinical Pathology. How I Diagnose Rosai-Dorfman Disease
When emperipolesis is sparse, or the biopsy is small, the diagnosis becomes considerably harder. In extranodal disease especially, the telltale RDD histiocytes can be scattered thinly among scar tissue and plasma cells, creating a picture that closely resembles IgG4-related disease, a chronic inflammatory condition. The overlap can be so convincing that molecular testing for MAPK/ERK pathway mutations sometimes becomes the tiebreaker.14American Journal of Clinical Pathology. How I Diagnose Rosai-Dorfman Disease
Why It Gets Mistaken for Lymphoma
RDD’s clinical behavior, presenting as enlarged lymph nodes in multiple locations, overlaps substantially with lymphoma. Documented misdiagnoses on needle aspirates include non-Hodgkin lymphoma, Hodgkin lymphoma, and nonspecific reactive lymph node enlargement.15PubMed Central. Pitfalls in Lymph Node Fine Needle Aspiration Cytology In at least one biopsy-proven case, the initial cytology reading suggested Hodgkin lymphoma.16PubMed. Fine needle aspiration (FNA) cytology of Rosai Dorfman disease The mistake is understandable: on a quick look, large abnormal cells surrounded by lymphocytes and plasma cells can superficially resemble Reed-Sternberg cells, the hallmark of Hodgkin disease. What separates them is the emperipolesis pattern and the immunostaining profile.
Even on PET scans, RDD lesions light up intensely, mimicking intermediate- or high-grade lymphomas.17Blood. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease – Section: Baseline evaluations This means that imaging alone cannot distinguish the two conditions; tissue biopsy remains essential. One case report described a patient whose RDD simultaneously mimicked both a malignant lymphoproliferative process and IgG4-related disease, requiring histopathology with S100 and CD1a staining to arrive at the correct diagnosis.18PubMed Central. A rare case of Rosai-Dorfman disease mimicking a malignant lymphoproliferative process and IgG4-related disease
The Role of Imaging
Once RDD is confirmed on biopsy, the question becomes how far the disease has spread. PET/CT scanning has proven useful here, not for making the initial diagnosis but for finding lesions that conventional CT or MRI might miss. In one retrospective study of 28 patients, PET/CT found previously undetected nodules and bone damage in several cases, and the information changed treatment plans for the vast majority of those who underwent follow-up scans.19PubMed Central. The value of (18)F-FDG PET/CT in the systemic evaluation of patients with Rosai-Dorfman disease: a retrospective study and literature review A separate study found PET/CT revealed previously unknown disease sites in about 40 percent of patients being assessed at initial diagnosis.20PubMed Central. Rosai-Dorfman Disease — Utility of F-18 FDG PET/CT for Initial Evaluation and Follow-up
Expert consensus recommends that the staging workup assess both disease extent and any associated conditions, particularly autoimmune disorders. When PET/CT is used, full-body scanning including the arms and legs is preferred over the standard skull-to-thigh range, because RDD can involve bones throughout the skeleton. That said, experts remain divided on whether PET/CT offers clear advantages over conventional anatomic imaging in every case.21Blood. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease – Section: Baseline evaluations
Treatment Depends on Where and How Severe
One of the most striking aspects of RDD is that many patients need no treatment at all. Between 20 and 50 percent of patients with nodal or cutaneous disease experience spontaneous remission.22Blood. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease – Section: Observation Watchful waiting is a legitimate first step for people whose disease is limited to uncomplicated lymph node swelling or asymptomatic skin lesions. In one large series, though, about 40 percent of patients initially placed on observation eventually did require treatment, so close monitoring remains important.23PubMed Central. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
When treatment is needed, the approach depends on whether the disease is localized or widespread and whether it threatens organ function.
- Surgery: For isolated, accessible lesions, surgical removal can be effective. A systematic review of cutaneous RDD found surgical excision was the most common intervention and achieved complete response in the vast majority of cases.24PubMed. Cutaneous Rosai-Dorfman disease: a systematic review and reappraisal of its treatment and prognosis However, about a third of initially operated patients in one large series later needed additional therapy, suggesting surgery does not always prevent recurrence.25PubMed Central. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
- Corticosteroids: Steroids can shrink swollen lymph nodes and ease symptoms, but the responses tend to be temporary, especially in extranodal disease. Doses in the range of 40 to 70 mg per day of prednisone have produced complete or partial responses in cases involving the orbits, central nervous system, bone, and autoimmune-associated disease.26Blood. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease – Section: Treatment
- Chemotherapy: Reserved for refractory or widespread disease. Traditional chemotherapy agents like anthracyclines and alkylating agents have shown little benefit. Nucleoside analogues such as cladribine and clofarabine have induced more durable remissions in severe or relapsed cases, though they carry significant bone marrow toxicity.27Blood. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease – Section: Treatment
Targeted Therapy and the Promise of MEK Inhibitors
The discovery of MAPK/ERK pathway mutations in a subset of RDD has opened a new therapeutic avenue. Cobimetinib, a drug that blocks the MEK protein in this signaling chain, has shown striking results in patients whose disease carries KRAS or MAP2K1 mutations. In a study of 16 patients treated with cobimetinib, the overall response rate was 63 percent. Among those whose tumors harbored KRAS or MEK gene alterations, the response rate jumped to 88 percent, with deep and lasting remissions. Patients without those mutations responded less often and progressed more quickly.28PubMed Central. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status
Individual case reports reinforce the point. One patient with a MAP2K1 mutation who had failed multiple prior therapies achieved a complete clinical and radiological response after 12 cycles of cobimetinib.29Oxford Medical Case Reports. Rosai–Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy This is the kind of result that has accelerated interest in genomic testing for patients with aggressive or treatment-resistant disease.30Blood. Rosai Dorfman’s Disease with MAP2K1 Mutation Refractory to Chemotherapy with Complete Response to MEK Inhibitor Therapy: A Case Report The practical implication is straightforward: if your RDD is not responding to steroids or conventional chemotherapy, mutational testing should be on the table, because a targetable mutation changes the treatment calculus entirely.
Overall Outlook
For most patients, the prognosis is good. Nodal and cutaneous disease tends to follow a benign, self-limiting course, though the clinical trajectory can be unpredictable, with the disease flaring and subsiding over years. In the largest historical case series, about 7 percent of patients died from direct complications, infections, or a secondary condition called amyloidosis. A later review placed mortality closer to 12 percent of cases.31Blood. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease – Section: Treatment course, disease surveillance, and prognosis The patients at highest risk are those with multifocal extranodal disease, especially involving the kidneys, liver, or lower respiratory tract. For that subgroup, aggressive treatment including systemic chemotherapy or targeted agents is often justified.
Autoimmune Overlap
About 10 percent of RDD cases coexist with some other immunologic condition.32PubMed Central. Autoimmune Diseases and Rosai-Dorfman Disease Coexist More Commonly than Expected: Two Case Reports The most commonly reported association is autoimmune hemolytic anemia, a condition in which the body’s immune system destroys its own red blood cells. Joint disease ranging from mild aches to disabling arthritis has also been documented, as have links to systemic lupus erythematosus and juvenile idiopathic arthritis.33Oxford Medical Case Reports. Rosai-Dorfman disease presenting as autoimmune hemolytic anemia in a male child in Palestine: a case report Rare cases have even been reported alongside lymphoma.34PubMed. Rare coexistence of Rosai-Dorfman disease and nodal marginal zone lymphoma complicated by severe life-threatening autoimmune hemolytic anemia
Whether RDD causes these autoimmune problems or whether a shared immune dysfunction produces both conditions simultaneously is still unclear. The practical takeaway for clinicians, and for patients, is that the baseline evaluation for RDD should include screening for autoimmune diseases, because catching an associated condition early can change how the disease is managed. If you develop new symptoms like joint pain, unusual fatigue, or unexplained anemia during the course of RDD, bring them up with your doctor rather than assuming they are unrelated.
Familial Cases and Unusual Patterns
RDD is almost always sporadic, appearing without any obvious family connection. Familial cases are exceedingly uncommon, which makes them all the more interesting when they do arise. A literature review identified a pair of brothers who both developed isolated bilateral orbital and paranasal sinus RDD, with both also having glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common inherited enzyme disorder.35PubMed. Isolated bilateral orbital and paranasal Rosai-Dorfman disease affecting two brothers: a case report and a systematic literature review Whether G6PD deficiency actually predisposes to RDD or this was coincidence in a small family cluster remains unknown. That same review identified 88 orbital RDD cases in the literature overall, underscoring just how rare this particular manifestation is. Orbital disease can be especially problematic because the mass effect within the bony eye socket can damage vision even when the disease is histologically benign.